albumin-interferon alpha2b fusion protein
/ FortuneRock (China)
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 01, 2021
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
(clinicaltrials.gov)
- P1/2; N=11; Completed; Sponsor: Tianjin SinoBiotech Ltd.; Recruiting ➔ Completed; Phase classification: P1 ➔ P1/2; N=32 ➔ 11
Enrollment change • Phase classification • Trial completion • Hepatitis B • Hepatology • Infectious Disease
1 to 1
Of
1
Go to page
1